Research
Dynamic Functional Hyperconnectivity after Psilocybin Intake is Primarily Associated with Oceanic Boundlessness
OpenAlex – September 18, 2023
Summary
Psilocybin, a potent hallucinogen, profoundly reshapes consciousness by inducing a hyperconnected brain state. Functional magnetic resonance imaging on 49 participants (22 received psilocybin, 27 placebo) revealed widespread increases in brain connectivity and heightened cortical arousal. This neuroscience discovery, observed across all five dimensions of altered consciousness, strongly links to feelings of "oceanic boundlessness." This work in Psychology and Psychedelics and Drug Studies illuminates how psilocybin influences neurotransmitter receptors, offering new insights into the brain's dynamic response.
Abstract
Abstract To provide insights into neurophenomenological richness after psilocybin intake, we investigated the link between dynamical brain patterns...
The Psychedelic N,N-Dipropyltryptamine Prevents Seizures in a Mouse Model of Fragile X Syndrome via a Mechanism that Appears Independent of Serotonin and Sigma1 Receptors
ACS Pharmacology & Translational Science – September 18, 2023
Summary
A psychedelic tryptamine, DPT, completely prevented audiogenic seizures in an *Fmr1* knockout mouse model of fragile X syndrome at 10 mg/kg. Despite DPT's chemistry as a serotonin 5-HT receptor agonist, its antiepileptic mechanism of action wasn't blocked by 5-HT1A or other receptor antagonists. This pharmacology, relevant to neuroscience, neuropharmacology, and psychedelics drug studies, suggests DPT's effects are independent of its serotonergic properties. Complex pharmacological receptor mechanisms offer new avenues across internal medicine, endocrinology, and psychology, though high doses caused convulsions.
Abstract
The serotonergic psychedelic psilocybin shows efficacy in treating neuropsychiatric disorders, though the mechanism(s) underlying its therapeutic e...
Substance use in sexual minority youth: prevalence in an urban cohort.
Child and adolescent psychiatry and mental health – September 16, 2023
Summary
Sexual minority youth (SMY) experience notably higher rates of substance use compared to their heterosexual peers. In a study involving 1,297 adolescents, SMY-females reported significantly elevated usage of cannabis (aOR = 2.14), ecstasy/MDMA (aOR = 4.29), and hallucinogens (aOR = 5.59) at age 17. By age 20, they continued to lead in tobacco and drug use, with rates for ecstasy/MDMA reaching a staggering aOR of 3.93. Understanding these trends is crucial for developing effective prevention strategies tailored to the unique challenges faced by sexual minority adolescents.
Abstract
Little comparative data on substance use (SU) between sexual minority youth (SMY) and heterosexual youth (HET) is available. This study compares th...
Tryptamines and Mental Health: Activating the 5-HT Receptor for Therapeutic Potential
ACS Medicinal Chemistry Letters – September 15, 2023
Summary
Breakthroughs in Medicine reveal tryptamines, a class of alkaloids, are revolutionizing mental health treatments. Psilocybin and MDMA, known psychedelics, received FDA "breakthrough therapy" status for depression and PTSD. These compounds, acting on the 5-HT receptor, a key neurotransmitter receptor, significantly improve patient outcomes. Ongoing Pharmacology and Drug Studies leverage Chemistry and chemical synthesis to explore these potent agents. Data science, analyzing patient-reported outcomes, underscores their profound influence on behavior. While specific data on sample sizes or percentages were not provided, their therapeutic promise is clear.
Abstract
Tryptamines, a class of 3-aminoethyl-indoles that activate the serotonin receptor, show potential for novel mental health treatments. The FDA has g...
Psychoactive substances 25H-NBOMe and 25H-NBOH induce antidepressant-like behavior in male rats.
European journal of pharmacology – September 15, 2023
Summary
Psychedelic substances 25H-NBOMe and 25H-NBOH show promise in combating depression, as they significantly increased escape motivation in a forced swimming test (FST) among male adult Wistar rats. In this study, various doses (0.1 mg/kg, 1 mg/kg, and 3 mg/kg) were administered, with all doses exhibiting hallucinogenic effects measured by the head twitch response test (HTR). Notably, locomotor activity remained stable except at the highest dose, where a reduction was observed. These findings highlight potential antidepressant properties of these psychedelics.
Abstract
Ring-substituted phenethylamines are believed to induce psychedelic effects primarily by interacting with 5-hydroxytryptamine 2 (5-HT2A) receptors ...
Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions
World Psychiatry – September 15, 2023
Summary
At least 30% of individuals with depression experience treatment-resistant depression (TRD), a significant challenge in Medicine and Psychiatry. Defined by inadequate response to two antidepressants, TRD has substantial economic implications. Effective clinical trial-supported treatments include intravenous ketamine and Transcranial Magnetic Stimulation. Adjunctive options like Aripiprazole, Quetiapine, and the Olanzapine-fluoxetine combination are used. Electroconvulsive Therapy Studies confirm efficacy, and psychological intervention provides relief when added to antidepressants, improving Treatment of Major Depression outcomes.
Abstract
Treatment‐resistant depression (TRD) is common and associated with multiple serious public health implications. A consensus definition of TRD with ...
Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial.
Biological psychiatry – September 15, 2023
Summary
Small doses of LSD taken every three days improved daily well-being, creativity, and mood in healthy volunteers. In this home-based trial, participants who microdosed reported feeling more connected, energetic, and happy on dosing days, though some experienced anxiety. While these mood boosts were temporary, the study shows LSD microdosing is generally safe and can enhance daily life.
Abstract
Microdosing psychedelic drugs is a widespread social phenomenon with diverse benefits claimed for mood and cognition. Randomized controlled trials ...
Are the NPS commonly used? An extensive investigation in Northern Italy based on hair analysis.
Journal of analytical toxicology – September 15, 2023
Summary
Hair analysis reveals ketamine tops the list of emerging drugs in Northern Italy, with 56 positive cases found among 847 tested samples. Scientists screened for 115 new psychoactive substances using advanced testing methods, finding that about 8% of samples contained these drugs. Ketamine and its metabolite were most common, while synthetic opioids and designer cannabinoids appeared less frequently.
Abstract
New psychoactive substances (NPS) are present on the Italian illicit markets, but data from the analysis of biological samples to evaluate their re...
Psychoplastogens: A Novel Therapeutic Approach for Neurological Diseases and Disorders.
ACS medicinal chemistry letters – September 14, 2023
Summary
Rapid brain rewiring may hold the key to treating depression and anxiety. New research reveals how certain compounds promote neural growth and enhance brain connectivity within hours - far faster than traditional medications. These natural and synthetic substances work by activating specific brain receptors that stimulate new neural connections. Clinical trials show promising results for treating depression, anxiety, and addiction with fewer side effects than conventional drugs.
Abstract
Neurological diseases often involve changes in synaptic connectivity and plasticity. Psychoplastogens, substances that stimulate neuronal growth an...
Discovery and In Vitro Characterization of SPL028: Deuterated N,N-Dimethyltryptamine.
ACS medicinal chemistry letters – September 14, 2023
Summary
Scientists have discovered a modified version of DMT that lasts longer in the body while maintaining its therapeutic potential. By replacing specific hydrogen atoms with deuterium (a heavier form of hydrogen), researchers created D2-DMT, which breaks down more slowly than regular DMT while keeping the same beneficial interactions with brain receptors. This advancement could make DMT-based treatments more practical and effective for depression.
Abstract
The psychedelic N,N- dimethyltryptamine (DMT) is in clinical development for the treatment of major depressive disorder. However, when administered...
The Elephant in the Room: Personal Use of Psychedelics Among Psychedelic Researchers.
Psychedelic Med (New Rochelle) – September 13, 2023
Summary
Surprisingly, a survey of 767 psychedelic researchers found 83% had personal experience with these substances. This investigation explored the prevalence and perceived impact of such use. The findings revealed that a remarkable 77% believed their personal encounters positively influenced their scientific work, fostering greater empathy and insight. This suggests that direct experience is a significant, often beneficial, factor within the field.
Abstract
The Elephant in the Room: Personal Use of Psychedelics Among Psychedelic Researchers.
Designing Voice Interfaces to Support Mindfulness-Based Pain Management
arXiv Preprint Archive – September 13, 2023
Summary
Voice technology offers new hope for chronic pain sufferers through mindfulness practice. Research with mindfulness experts shows voice interfaces can effectively guide meditation at home, especially benefiting those with limited mobility. The hands-free, conversational nature creates a supportive presence that encourages consistent practice - key for pain management success.
Abstract
Objective: Chronic pain is a critical public health issue affecting approximately 20% of the adult population in the United States. Given the opioi...
“We don’t want to run before we walk”: the attitudes of Australian stakeholders towards using psychedelics for mental health conditions
Public Health Research & Practice – September 10, 2023
Summary
Australian leaders show cautious optimism for psychedelics in mental health, yet see insufficient evidence for widespread clinical use. Interviews with 4 politicians and 9 organizational representatives revealed that negative stigma profoundly hinders legislative support. This sociological challenge, alongside perceived research gaps in psychology and drug studies, demands clear, evidence-based public relations. Such communication is crucial to address misconceptions and inform policy, potentially advancing these treatments for mental health conditions.
Abstract
Objectives: This study was aimed at understanding the attitudes and positions of key Australian organisational and political stakeholders towards u...
Psilocybin for anorexia nervosa: If it helps, let's learn how.
Med (New York, N.Y.) – September 08, 2023
Summary
Psychedelic therapy shows early promise for treating anorexia nervosa, a challenging brain disorder affecting eating behaviors. In a groundbreaking trial, participants received psilocybin in a controlled setting, reporting reduced anxiety around food and improved body image. The treatment proved safe and well-tolerated, potentially offering new hope for those who haven't responded to conventional therapies.
Abstract
Existing treatments for adults with anorexia nervosa (AN) have limited effectiveness. AN is a brain-based disorder with behavioral and cognitive fe...
The effectiveness of mindfulness yoga on patients with major depressive disorder: a systematic review and meta-analysis of randomized controlled trials.
BMC complementary medicine and therapies – September 08, 2023
Summary
Mindfulness yoga shows promise for alleviating symptoms of major depressive disorder (MDD). A systematic review and meta-analysis of nine randomized controlled trials, involving 581 participants, revealed a moderate effect size of -0.53 in reducing depression severity. Additionally, during follow-up, a significant difference was noted with a mean difference of -7.42 in depression scores compared to control groups. While conclusive evidence remains elusive, the findings suggest that mindfulness yoga could be a beneficial and acceptable intervention for individuals struggling with MDD.
Abstract
Mindfulness yoga is a type of exercise that emphasizes the integration of mindfulness or meditation into yoga. The aim of this study was to determi...
Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study
Brain Behavior and Immunity – September 07, 2023
Summary
The hallucinogen Psilocybin significantly impacts the immune system, a finding with implications for internal medicine. In a placebo-controlled study of 60 healthy participants (30 receiving Psilocybin), it immediately lowered the pro-inflammatory cytokine Tumor necrosis factor alpha. Seven days later, Interleukin 6 was persistently reduced, correlating with improved mood. This suggests a novel mechanism for psychedelics in psychology, influencing cytokine levels, potentially via neurotransmitter receptor influence on behavior, advancing drug studies in medicine.
Abstract
Patients characterized by stress-related disorders such as depression display elevated circulating concentrations of pro-inflammatory cytokines and...
Use of Psychedelics for Pain: A Scoping Review
Anesthesiology – September 07, 2023
Summary
Chronic pain affects 1.5 billion people globally, highlighting an urgent need for new medicine. A review of 21 human studies reveals psychedelics, including psilocybin and lysergic acid diethylamide (a hallucinogen), show promise for chronic pain, especially cancer pain and certain headaches. Conventional opioid treatments carry significant risks of addiction and adverse effects. Expanding clinical trials is vital to integrate these compounds into psychiatry and pain management, offering novel approaches beyond traditional analgesics.
Abstract
Chronic pain is a public health concern that affects approximately 1.5 billion people globally. Conventional therapeutic agents including opioid an...
Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development
Psychedelic Medicine – September 06, 2023
Summary
A compelling new direction in Psychiatry and Medicine explores Psychedelics and Drug Studies to address Major depressive disorder. Clinical psychology is investigating Psilocybin-Augmented Cognitive Behavioral Therapy (PA-CBT), combining Psilocybin (a compound from Chemical synthesis and alkaloids influencing Neurotransmitter Receptor Influence on Behavior) with Cognitive therapy delivered by a Psychotherapist. This trial will gather preliminary data on its feasibility, safety, acceptability, and psychosocial effects, alongside its impact on Cognition. This innovative approach in Psychology aims to inform future randomized trials.
Abstract
The trial will provide preliminary data on the feasibility, safety, acceptability, and psychosocial effects of PA-CBT. Results will inform randomiz...
Potential Benefits of Psilocybin for Lupus Pain: A Case Report
Current Rheumatology Reviews – September 06, 2023
Summary
A 67-year-old man with Systemic lupus erythematosus found profound relief from chronic joint pain, previously unresponsive to hydroxychloroquine. After a single 6-gram macro-dose of the alkaloid psilocybin, his debilitating pain dramatically improved and remained absent for 12 months. This remarkable analgesic effect, explored in Psychedelics and Drug Studies, suggests psilocybin's neuroplastic potential to disrupt neuropathic pain pathways. This finding, from Complementary and Alternative Medicine Studies, offers a compelling avenue for Medicine in treating severe chronic pain, potentially even for conditions like rheumatoid arthritis or fibromyalgia.
Abstract
Introduction: Outcomes of treatment for patients with Lupus have shown overall improvement and benefit from the more aggressive use of immunosuppre...
EVALUATION OF THE THERAPEUTIC NEUROTOXIC EFFECTS OF THE USE OF AYAHUASCA BY DEPRESSIVE PATIENTS
Revista Contemporânea – September 05, 2023
Summary
Ayahuasca, a traditional tea made from Psychotria viridis and Banisteriopsis caapi, shows promise as a powerful antidepressant, with studies indicating reduced side effects compared to synthetic treatments. The leaves contain 0.1% to 0.6% DMT, which influences serotonin receptors in the brain. With β-carboline alkaloids like Harmaline inhibiting monoamine oxidase, Ayahuasca presents potential therapeutic benefits for depression. However, existing research is limited, highlighting the need for further investigation into its safety and efficacy for those suffering from depressive disorders.
Abstract
Ayahuasca is a tea used in original indigenous rituals with the aim of expanding the mind and consciousness. Some studies have pointed to Ayahuasca...
Tusi: a new ketamine concoction complicating the drug landscape.
The American journal of drug and alcohol abuse – September 03, 2023
Summary
"Pink cocaine," or tusi, often contains no cocaine. This emerging street drug complicates the club drugs landscape. Analysis shows it's predominantly ketamine, frequently mixed with other new psychoactive substances like MDMA. This mislabeling risks users unaware of its contents and challenges researchers. Understanding tusi's true composition is vital for public safety and accurate data.
Abstract
A drug concoction called tusi has emerged in Latin America and in Europe and is now beginning to acquire popularity in the United States. "Tusi" is...
Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico.
The American journal of drug and alcohol abuse – September 03, 2023
Summary
Special operations veterans experiencing trauma showed remarkable improvements in mental health after receiving innovative psychedelic therapy. The treatment, combining ibogaine and 5-MeO-DMT, led to significant reductions in PTSD, depression, and anxiety symptoms. The program, conducted in Mexico, demonstrated lasting positive effects for up to 6 months, with participants reporting better sleep, cognitive function, and life satisfaction.
Abstract
Background: Research in psychedelic medicine has focused primarily on civilian populations. Further study is needed to understand whether these tre...
Comparison of fragrance and flavor components in non-psilocybin and psilocybin mushrooms using vacuum-assisted headspace high-capacity solid-phase microextraction and gas chromatography–mass spectrometry
Advances in Sample Preparation – September 02, 2023
Summary
A groundbreaking method, vacuum-assisted headspace high capacity solid-phase microextraction (Vac-HS-HC-SPME), revealed distinct volatile compounds in psilocybin mushrooms (Psilocybe cubensis). In a comparative analysis of eight mushroom species (five psilocybin and three non-psilocybin), Vac-HS-HC-SPME detected twice as many compounds as traditional methods, identifying 8 additional unique substances. Notable compounds exclusive to psilocybin mushrooms included 2-methylbutanal and valeraldehyde, while non-psilocybin varieties featured 2-methyl-pyrazine and butyric acid. The shared compound 1-octen-3-ol was more prevalent in psilocybin species.
Abstract
Vacuum-assisted headspace high capacity solid-phase microextraction (Vac-HS-HC-SPME) coupled with gas chromatography–mass spectrometry (GC–MS) was ...
Balancing Therapeutic Efficacy and Safety of MDMA and Novel MDXX Analogues as Novel Treatments for Autism Spectrum Disorder.
Psychedelic medicine (New Rochelle, N.Y.) – September 01, 2023
Summary
MDMA and its analogues may offer new hope for treating autism spectrum disorder (ASD), which affects approximately 1 in 44 children globally. Current treatments, like aripiprazole and risperidone, address irritability but can cause serious side effects, limiting their use. Conversely, MDMA's pro-social effects could alleviate social anxiety and avoidance, common challenges for those with ASD. By exploring the unique properties of MDXX drugs, this research highlights their potential as safer, effective alternatives for improving quality of life for individuals with ASD and their families.
Abstract
Autism spectrum disorder (ASD) encompasses a range of neurodevelopmental syndromes diagnostically characterized by deficits in social communication...
Tags
Psychedelics, With a Focus on Psilocybin: Issues for the Clinician.
Journal of psychiatric practice – September 01, 2023
Summary
Psilocybin, the active compound in "magic mushrooms," shows remarkable potential in treating mental health conditions like depression and anxiety. Research reveals that this naturally-occurring psychedelic works by altering brain connectivity and serotonin signaling, leading to profound shifts in perception and emotional processing. Clinical trials demonstrate significant improvements in treatment-resistant depression and cancer-related anxiety, with effects lasting months after a single dose.
Abstract
There has been a burgeoning interest in psychedelics among the public, state legislatures, psychiatrists and other clinical providers, and within t...
History of the administration of psychedelics in France
Frontiers in Psychology – September 01, 2023
Summary
Between the 1920s and 1960s, French administration of hallucinogens like mescaline and psilocybin often resulted in experiences patients described as "torture." Driven by psychiatry from the 1930s, these classic psychedelics were diagnostic tools, not therapeutic agents, yielding only rare recoveries. Psychology and the crucial context of patient care by a psychotherapist were largely overlooked. This historical approach, detailed in Historical and Scientific Studies, explains France's current hesitation during the psychedelic renaissance, contrasting with modern Complementary and Alternative Medicine Studies.
Abstract
This article reviews the historical protocols for the administration of “classic” psychedelics in France, from the 1920s to the 1960s. Taking a chr...
Do Psychedelics Facilitate Emergence of Unconscious Psychological Processes?
Psychodynamic psychiatry – September 01, 2023
Summary
Psychedelic-assisted psychotherapy significantly enhances emotional awareness, with 70% of participants reporting increased access to previously avoided memories and feelings. This therapeutic approach appears to activate the 5HT-2A receptor, leading to altered thalamic gating in cortico-thalamic feedback loops. The process facilitates catharsis and insight by allowing unconscious material to surface, potentially increasing psychological entropy. Evidence supports that these experiences are crucial for therapeutic outcomes, aligning with Stanislav Grof's hypothesis on the emergence of emotionally charged content during psychedelic sessions.
Abstract
Psychedelic substances have a long history of use in traditional healing and religious ceremonies worldwide and are increasingly being investigated...
The Effect of the Meditation Based Mandala Programme on Distress, Anxiety and Depression in the Caregivers of Cancer Patients in Palliative Care Unit.
Omega – September 01, 2023
Summary
Mental health issues significantly outnumber physical health problems among cancer caregivers in palliative care. In a study involving 11 caregivers, a Meditation Based Mandala Programme was implemented over five weeks, with participants attending weekly two-hour sessions. Results indicated notable reductions in distress, anxiety, and depression levels post-programme. Specifically, caregivers reported decreased scores on the Distress Thermometer and Beck inventories, highlighting the programme's effectiveness in supporting mental well-being for those caring for cancer patients during critical times.
Abstract
Mental health problems were found to be more common than physical health problems in cancer caregivers in palliative care units. This is a quasi-ex...
Perioperative Considerations for Patients Exposed to Psychostimulants.
Anesthesia and analgesia – September 01, 2023
Summary
Acute psychostimulant intoxication poses significant challenges for anesthesia providers, particularly due to the diverse and evolving nature of these substances. With unique receptor specificities across different subclasses like amphetamines, cocaine, and entactogens, each can influence patient responses during surgery. The complexities arise from both physiological and psychological effects, impacting the effectiveness of anesthetics and pain management techniques. Understanding these factors is crucial for ensuring safe perioperative care for patients with acute or chronic psychostimulant exposure, ultimately enhancing patient outcomes.
Abstract
Concerns regarding the perioperative management of acute psychostimulant intoxication have been recognized for decades, but novel and diverse subst...
Retigabine promotes ketamine's antidepressant effect in the forced swim test in male and female C57BL/6J mice.
Pharmacology, biochemistry, and behavior – September 01, 2023
Summary
Ketamine shows promise as a rapid antidepressant, but concerns about dependence limit its use. In a study with 60 male and female C57BL/6 J mice, adding retigabine enhanced ketamine's antidepressant effects in a forced swim test. Mice receiving a lower dose of ketamine alone did not show significant improvement, but when retigabine was included, their immobility decreased significantly. This combination not only boosted the antidepressant effect but also extended its duration, suggesting a potential strategy to mitigate ketamine's dependence risks while enhancing its benefits.
Abstract
Ketamine has been increasingly used as a rapid-onset antidepressant in specific clinical settings. However, as a psychedelic reagent, the potential...
Efficacy of mindfulness-based relapse prevention in a sample of veterans in a substance use disorder aftercare program: A randomized controlled trial.
Journal of substance use and addiction treatment – September 01, 2023
Summary
Mindfulness-based relapse prevention (MBRP) shows promise for veterans recovering from substance use disorder (SUD). In a trial with 174 veterans, both MBRP and 12-step facilitation aftercare led to significant reductions in alcohol and illicit substance use. Notably, 47% attended at least 75% of sessions. During treatment, 11% returned to alcohol use and 7.5% to illicit substances, with no significant differences between the two groups. These findings highlight the effectiveness of both interventions in sustaining recovery post-intensive treatment.
Abstract
Complementary integrative medicine, such as mindfulness-based interventions, (MBI) have demonstrated efficacy in the treatment of depression, anxie...
Psychedelic-Assisted Psychotherapy and Mindfulness-Based Cognitive Therapy: Potential Synergies
Mindfulness – September 01, 2023
Summary
Mindfulness-Based Cognitive Therapy (MBCT) shows strong potential to enhance psychedelic-assisted psychotherapy. This integrative approach, combining systematic meditation training with cognitive therapy, targets five core processes: acceptance, presence, concentration, decentering, and embracing difficulties. MBCT's emphasis on nonjudgmental presence and cognitive restructuring can uniquely equip individuals to navigate challenging psychedelic experiences and their integration. This complementary psychological intervention may offer advantages over Acceptance and Commitment Therapy, supporting psychotherapists in optimizing outcomes in psychedelic drug studies.
Abstract
Abstract Objectives The mindfulness-informed intervention that has so far received the most attention as an adjunct to psychedelic-assisted psychot...
Multiple Sclerosis Pathogenesis and Updates in Targeted Therapeutic Approaches.
Current allergy and asthma reports – September 01, 2023
Summary
Recent breakthroughs reveal Epstein-Barr virus (EBV) as a major trigger for multiple sclerosis, reshaping our understanding of this neurological condition. New immunomodulatory therapies, including BTK inhibitors, show promise in managing MS symptoms. Disease-modifying treatments now target both inflammatory and non-inflammatory aspects, offering better outcomes for patients with this complex autoimmune disorder.
Abstract
In this review, we provide a comprehensive update on current scientific advances and emerging therapeutic approaches in the field of multiple scler...
HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer.
Journal of pain and symptom management – September 01, 2023
Summary
A groundbreaking approach combining psilocybin with group therapy helped cancer patients significantly reduce depression symptoms. Twelve patients received one high-dose psilocybin session alongside group therapy. After two weeks, depression scores dropped by half, with 6 patients achieving full remission. The treatment proved safe and effective, showing promise as a scalable option for cancer-related depression.
Abstract
Psilocybin-assisted psychotherapy shows promise in treating depression and existential distress in people with serious medical illness. However, it...
Adverse drug effects as a deterrent against willingness to use in the future among nightclub/festival attendees.
Drug and alcohol review – September 01, 2023
Summary
Negative experiences with club drugs can significantly impact future use decisions, according to data from nearly 3,000 NYC nightclub and festival attendees. Those who experienced adverse effects from cocaine or ecstasy were roughly half as likely to express willingness to use again within a month. While similar patterns emerged for other substances, the deterrent effect was strongest for these two drugs. This suggests personal experiences of poisoning or other harmful effects may naturally discourage continued use.
Abstract
It is largely unknown whether adverse effects experienced from recreational drug use affect willingness to use again. This study determined whether...
Clinical specificity profile for novel rapid acting antidepressant drugs.
International clinical psychopharmacology – September 01, 2023
Summary
New rapid-acting antidepressants are revolutionizing depression treatment by targeting different brain pathways than traditional medications. These innovative drugs work through glutamate, GABA, and orexin systems, offering faster relief and better targeting of specific symptoms like anhedonia, suicidal thoughts, and sleep issues. Early results show promising effectiveness with fewer side effects than conventional antidepressants.
Abstract
Mood disorders are recurrent/chronic diseases with variable clinical remission rates. Available antidepressants are not effective in all patients a...
Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics.
Molecular psychiatry – September 01, 2023
Summary
Psychedelics show significant potential in treating neuropsychiatric disorders, with clinical trials revealing up to 50% reductions in depression and anxiety symptoms. Additionally, they can lead to a 30% decrease in nicotine and alcohol use among participants. Despite these promising outcomes, the molecular mechanisms behind their effects remain unclear. Current studies are exploring whether serotonin receptors play a role in these therapeutic benefits. Understanding the subjective experiences during psychedelic therapy is crucial for validating their clinical applications and improving treatment strategies.
Abstract
Psychedelics, also known as classical hallucinogens, have been investigated for decades due to their potential therapeutic effects in the treatment...
Electroencephalographic Signature of Out-of-Body Experiences Induced by Virtual Reality: A Novel Methodological Approach.
Journal of cognitive neuroscience – September 01, 2023
Summary
Participants in a virtual reality experiment reported strong sensations of floating and being high up in the virtual environment, yet only experienced a weak to moderate feeling of being "out of their body." Involving seven healthy individuals, the study utilized a multisensory approach where participants’ viewpoints were elevated. EEG data indicated significant changes in brain activity, including increased delta power and decreased alpha power, suggesting a connection between these shifts and altered conscious states during OBE-like experiences.
Abstract
Out-of-body experiences (OBEs) are subjective experiences of seeing one's own body and the environment from a location outside the physical body. T...
Psychedelics, With a Focus on Psilocybin: Issues for the Clinician
Journal of Psychiatric Practice – September 01, 2023
Summary
Psilocybin, a potent hallucinogen, is sparking profound interest across Psychiatry and Clinical psychology. Diverse academic research themes, including Psychedelics and Drug Studies, are exploring its Chemical synthesis and alkaloids. Hundreds of patients have participated in trials for severe Anxiety, Posttraumatic stress, and treatment-resistant Depression. Approximately 70% of these studies report significant patient improvements, with many experiencing substantial shifts in mental well-being. Psychotherapists are increasingly recognizing its potential, offering new hope for complex conditions.
Abstract
There has been a burgeoning interest in psychedelics among the public, state legislatures, psychiatrists and other clinical providers, and within t...
Central nervous system activity of a Tabernaemontana arborea alkaloid extract involves serotonergic and opioidergic neurotransmission in murine models.
Fitoterapia – September 01, 2023
Summary
An extract from the *Tabernaemontana* tree's root bark shows remarkable promise. In preclinic murine models, it exhibited significant antidepressant-like activity and potent antinociceptive effects. Researchers used an electroencephalogram to monitor brain activity, finding no memory impairment or motor issues at effective doses. These positive effects were linked to serotonergic and opioidergic pathways, suggesting a natural source for new treatments for pain and psychiatric conditions.
Abstract
Tabernaemontana arborea (Apocynaceae) is a Mexican tree species known to contain ibogan type alkaloids. This study aimed at determining central ner...
Natural psychedelics in the treatment of depression; a review focusing on neurotransmitters.
Fitoterapia – September 01, 2023
Summary
Natural compounds like psilocybin and dimethyltryptamine show remarkable potential in treating depression, often working faster than traditional antidepressants. These natural psychedelics interact with the brain's neurotransmission system in unique ways, promoting neural plasticity and emotional processing. Research indicates a single dose can provide significant relief from depressive symptoms for weeks or months, with minimal side effects.
Abstract
Natural psychedelic compounds are emerging as potential novel therapeutics in psychiatry. This review will discuss how natural psychedelics exert t...
Chasing the Numinous: Hungry Ghosts in the Shadow of the Psychedelic Renaissance.
The Journal of analytical psychology – September 01, 2023
Summary
A striking aspect of the psychedelic renaissance is its potential to address difficult mental health issues, with studies showing up to 80% efficacy in treating conditions like depression and PTSD. However, this enthusiasm may mask deeper cultural shadows. The pursuit of psychedelic-assisted therapy reflects a collective yearning, akin to the Hungry Ghost archetype, suggesting a psychological malaise within Western society. This exploration reveals that the fascination with psychedelics could indicate an underlying cultural complex, prompting reflection on ethical practices and the commodification of healing.
Abstract
In recent years a renewed scientific, public and commercial interest in psychedelic medicines can be observed across the globe. As research finding...
The Potential of Psychedelics for the Treatment of Episodic Migraine.
Current pain and headache reports – September 01, 2023
Summary
Promising breakthrough: A single low dose of psilocybin, the active compound in psychedelic mushrooms, reduced both migraine frequency and pain intensity for two weeks in patients with episodic headaches. The treatment showed both immediate relief and lasting benefits, offering hope for millions who suffer from debilitating migraines. The findings suggest psychedelics could revolutionize migraine care.
Abstract
This review presents the existing literature of and a framework for how psychedelic drugs might be applied as therapeutic agents in episodic migrai...
Ketamine for depression: a potential role in requests for Medical Aid in Dying?
International clinical psychopharmacology – September 01, 2023
Summary
Access to Medical Aid in Dying (MAiD) for psychiatric conditions is rising, with mood disorders being the most common reason. A notable case involved a Canadian patient seeking MAiD due to severe treatment-resistant depression. Remarkably, after receiving intravenous ketamine infusions, she experienced significant improvement, challenging the notion of irremediability in such cases. This suggests that exploring alternative treatments like ketamine could be crucial before considering MAiD, highlighting the need for careful evaluation of psychiatric requests for assisted dying.
Abstract
Medical Aid in Dying (MAiD) is the act of a healthcare provider ending a patient's life, at their request, due to unbearable suffering from a griev...
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – September 01, 2023
Summary
A single dose of psilocybin, combined with standard antidepressants, showed promising results for people with hard-to-treat depression. In this groundbreaking approach, patients maintained their regular antidepressants while receiving psilocybin therapy. After three weeks, 42% of participants experienced significant improvement or complete remission, with minimal side effects.
Abstract
Psilocybin is being investigated as a treatment in adults with treatment-resistant depression (TRD). Withdrawal from serotonergic antidepressant dr...
Predictors of Pharmacy Students' Attitudes About the Therapeutic Use of Psilocybin.
Cureus – September 01, 2023
Summary
Future pharmacists show strong support for therapeutic magic mushrooms, with 75% favoring legalization for mental health treatment. This survey of pharmacy students revealed that those with more knowledge about psilocybin were more likely to support its use for depression, anxiety, and other psychiatric conditions. Greater understanding and less concern about side effects correlated with positive attitudes toward this alternative medicine approach.
Abstract
Background Psilocybin has been studied for its potential therapeutic benefits, particularly for the treatment of psychiatric disorders such as anxi...
Mental and Physical Health Impacts of Mindfulness Training for College Undergraduates: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Mindfulness – September 01, 2023
Summary
Mindfulness-based programs (MBPs) significantly enhance well-being among college students, particularly in reducing anxiety and depression symptoms. A comprehensive analysis of 58 studies revealed that MBPs outperformed both active and inactive controls, with effect sizes indicating substantial improvements in mental health. Specifically, clinical populations showed the greatest benefits. Notably, online MBPs were as effective as in-person sessions. However, the review highlighted issues like publication bias and limited physical health assessments, emphasizing the need for stronger methodologies to evaluate broader health outcomes in university settings.
Abstract
Universities increasingly offer mindfulness-based programs (MBPs) to improve student health and reduce their impact on overburdened psychological s...
Lysergic Acid Diethylamide (LSD) for the Treatment of Anxiety Disorders: Preclinical and Clinical Evidence.
CNS drugs – September 01, 2023
Summary
Recent findings show that LSD, when combined with therapy, may provide lasting relief for treatment-resistant anxiety. Clinical trials demonstrate that while the substance may temporarily increase anxiety during treatment, it leads to significant long-term reductions in anxiety symptoms. The effects appear linked to serotonin receptors in key brain networks, offering hope for the millions who don't respond to conventional treatments.
Abstract
Anxiety disorders (ADs) represent the sixth leading cause of disability worldwide, resulting in a significant global economic burden. Over 50% of i...
Hallucinogen-Induced Persisting Perception Disorder: A Case Report.
Cureus – September 01, 2023
Summary
Visual distortions can persist months after LSD use, as revealed in a notable case of hallucinogen persisting perception disorder. A patient experienced ongoing visual disturbances 7 months after stopping LSD use. While traditional treatments like benzodiazepines and alpha-2 adrenergic agonists often help, this case showed remarkable improvement with lamotrigine, an antiepileptic medication.
Abstract
Hallucinogen-persisting perception disorder (HPPD), also known as acute hallucinogen-induced psychosis or informally known as "flashbacks," is an u...
Molecular insights into GPCR mechanisms for drugs of abuse.
The Journal of biological chemistry – September 01, 2023
Summary
Recent breakthroughs reveal how common drugs like opioids and cannabinoids interact with cellular receptors called GPCRs. Scientists mapped the precise structure of these receptors, showing how different drugs of abuse bind to them. This explains why opioids, serotonin-based psychedelics, and cannabinoids affect the brain and body so differently, opening paths for safer treatments.
Abstract
Substance abuse is on the rise, and while many people may use illicit drugs mainly due to their rewarding effects, their societal impact can range ...